New hope for wrinkles

Dec 15, 2006

A new anti-aging ingredient developed by Australian researchers is expected to be available in skin products next year. The new additive - gamma glutamyl cysteine (GGC) - is a precursor for an effective antioxidant known as glutathione, which has a broad range of potential health benefits.

Glutathione is the body's key defense for detoxifying harmful compounds implicated in cancer, diabetes, aging along with other diseases and degenerative conditions.

After nine years in development, researchers Dr Wallace Bridge and Dr Martin Zarka, of the University of New Sotuh Wales (Sydney, Australia) have established a new, cost-effective process for manufacturing GGC.

The process has been licensed to pharmaceutical company, Biospecialties Australia. A newly-expanded manufacturing plant at Newcastle, New South Wales, will produce GGC.

It is expected that GGC will be used as an active ingredient in foods, health care, toothpastes, dietary supplements and cosmetics as well as in skin repair anti-aging creams.

Natural dietary sources of GGC are available, including milk whey protein and garlic.

However, GGC is present only in relatively dilute concentrations. This new, pure GGC product will potentially allow for more efficacious dosages and product formulations.

Given the rapidly increasing interest in glutathione, it is likely a pure GGC supplement would have significant market potential.

Biospecialties Australia P/L is a licensee of New South Innovations (NSi), which provides technology transfer services to the university.

The company received an Australian Government "Commercial Ready" grant of A$1.1M earlier this year to assist in bringing GGC to market for use in foods, health care and cosmetics.

Source: University of New South Wales

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.